Out of the 65 screened subjects, 59 eligible subjects were randomized and completed the study. The study consisted of two different dosages of Phyllanthus emblica extract - 250 mg and 500 mg twice daily. Both dosages showed significant improvement in endothelial function (vascular health), oxidative stress biomarkers-Nitric oxide (+ 41.89%, + 50.7%), Glutathione (+ 24.31%, + 53.22%), Malondialdehyde (- 21.02%, - 31.44%), and systemic inflammation biomarker, hsCRP (- 39.68%, - 53.77%) at 12 weeks with 250 mg and 500 mg twice daily dosage respectively, compared to baseline and placebo. Results also showed a significant mean percent change at 12 weeks with total cholesterol (- 7.71%, - 11.11%), HDL-C (+ 7.33% + 22.16%), LDL-C (- 11.39%, - 21.8%) and Triglycerides (- 9.81%, - 19.22%) respectively with 250 mg and 500 mg twice daily. The 500 mg twice daily dose was significantly more efficacious than the 250 mg twice daily dose and placebo. Thus, this product may be used as an adjunct to conventional therapy (lifestyle modification and pharmacological intervention) in the management of metabolic syndrome.
Dr. Sanni Raju, CEO of Natreon, stated that “Capros has all the attributes of being an excellent heart health product and has been consistently proven to be so in multiple clinical studies. This latest trial once again has shown the ability of Capros to improve vascular health, reduce oxidative stress, improve the lipid profile, especially by reducing the LDL and triglycerides. It also has shown to enhance immune response by reducing hsCRP and improve blood flow.”
Raju also says that “Capros is a totally natural and vegan edible fruit aqueous extract and when combined with its recently issued US Patent (8,962,576) on composition and methods for improving endothelial function and cardiovascular health, Capros’ solubility, stability, and taste, make it an ideal heart health product for capsule, powder and beverage formations.”